Program Description & Educational Objectives
In this 2-part activity, experts in the treatment of retinal vein occlusion discuss current trends in the diagnosis and management of this condition and the practical applications of recent and late-breaking data with respect to pharmacologic therapies for the treatment of macular edema secondary to retinal vein occlusion. Highlights of this program include an analysis of a survey fielded to ophthalmologists and retina specialists designed to probe how these practitioners are currently diagnosing and treating retinal vein occlusion. Case vignettes are also used to assist practitioners in translating the latest clinical evidence with respect to emerging pharmacologic therapies into practice for the management of this condition.
Upon completion of this activity, participants should be better able to:
- Apply the most recent clinical information on relative benefits and risks of standard and emerging therapies for retinal vein occlusion to point-of-care actions
- Create individualized treatment regimens for patients with retinal vein occlusion, based on specific patient and disease factors
- Integrate novel and emerging therapies into regimens for patients with retinal vein occlusion, as validated by clinical evidence
Target Audience
This activity has been designed to meet the educational needs of ophthalmologists, retina specialists, and other clinicians involved in the management of patients with retinal vein occlusion.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: March 17, 2010 - March 16, 2011
Time to Complete: 30 minutes
Faculty & Disclosure
Course Director and Interviewee
David M. Brown, MD, FACS
Clinical Assistant Professor
Department of Ophthalmology
The Methodist Hospital, Weill College of Medicine, Cornell University
Director of Clinical Research at the Greater Houston Retina Research Center
Private Practice at Retina Consultants of Houston
Houston, Texas
David M. Brown, MD, FACS,
has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.
Grant/Research Support from Alcon Laboratories, Inc.; Alimera Sciences; Allergan, Inc.; Eli Lilly and Company; Genentech, Inc.; Jerini AG; Neurotech; NeoVista, Inc., Novartis Pharmaceuticals Corporation; Othera Pharmaceuticals; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Schering-Plough Corporation; Sirion Therapeutics, Inc.; TargeGen Inc., and ThromboGenics.
Honoraria from Genentech, Inc.; NeoVista, Inc., Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.
Advisory Board for Allergan, Inc. and Genentech, Inc.
Other Financial or Material Support from editorial board involvement in Retina Today and Retinal Physician.
Interviewee
Michael S. Ip, MD
Associate Professor
University of Wisconsin
Department of Ophthalmology
Fundus Photograph Reading Center
Madison, Wisconsin
Michael S. Ip, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Notal Vision; QLT Inc.; and Sirion Therapeutics, Inc.
Grant/Research Support from Allergan, Inc. and National Eye Institute.
Content Director
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education, Inc.
Kirk A. Tacka, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Genentech, Inc.
